Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Antiretrovirals and Weight Change: Weighing the Evidence
David A. Wohl, John R. Koethe, Paul E. Sax, et al.
Clinical Infectious Diseases (2024) Vol. 79, Iss. 4, pp. 999-1005
Closed Access | Times Cited: 18

Showing 18 citing articles:

Bictegravir/emtricitabine/tenofovir alafenamide in clinical practice for people with HIV: final 24-month effectiveness and safety outcomes in key populations in the observational BICSTaR cohort
Benoît Trottier, Chia‐Jui Yang, Dai Watanabe, et al.
HIV Research & Clinical Practice (2025) Vol. 26, Iss. 1
Open Access | Times Cited: 1
Metabolic Complications After Initiating BIC/FTC/TAF Versus DTG + 3TC in ART-naive Adults With Human Immunodeficiency Virus (HIV): A Multicenter Prospective Cohort Study
Alejandro García, Miguel Suárez Robles, Maria Jesús Pérez‐Elías, et al.
Clinical Infectious Diseases (2025)
Closed Access | Times Cited: 1
Choice of antiretroviral therapy has low impact on weight gain
Henning Drechsler, Colby Ayers, Ikwo Oboho, et al.
AIDS (2024) Vol. 38, Iss. 12, pp. 1731-1739
Closed Access | Times Cited: 5
Efficacy and safety of switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir/abacavir/lamivudine: Results from an open-label extension of a phase 3 randomized, double-blind, multicenter, active-controlled, non-inferiority study
Indira Brar, Peter Ruane, Mezgebe Berhe, et al.
Medicine (2025) Vol. 104, Iss. 8, pp. e41482-e41482
Open Access
Change in weight and BMI associated with switching to bictegravir/emtricitabine/tenofovir alafenamide versus a dolutegravir-based regimen among virologically suppressed adults living with HIV through 144 weeks
Charlotte-Paige Rolle, Jeffrey Garrett, Jamie Castano, et al.
Medicine (2025) Vol. 104, Iss. 10, pp. e41728-e41728
Open Access
Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide in Black and Hispanic/Latine adults with HIV‐1 initiating first‐line therapy: 5‐year follow‐up from two phase III studies
Claudia Martorell, Moti Ramgopal, D Hagins, et al.
HIV Medicine (2025)
Open Access
Long-term metabolic changes with bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir-containing regimens for HIV
Eric S. Daar, Chloe Orkin, Paul E. Sax, et al.
AIDS Research and Therapy (2025) Vol. 22, Iss. 1
Open Access
Integrase strand transfer inhibitors, their impact in adipose tissue and weight gain in people living with HIV - A narrative review
María Magdalena Valle-Hernández, Elba Reyes Maldonado, José Antonio Mata‐Marín, et al.
Nutrición Hospitalaria (2025)
Open Access
Strategies for choice of antiretroviral therapy in patients with HIV infection and concomitant cardiovascular disease: A review
V.I. Shakhgildyan, С.Т. Мацкеплишвили
Terapevticheskii arkhiv (2025) Vol. 97, Iss. 04, pp. 367-377
Open Access
Which form of tenofovir should be used worldwide: TDF or TAF?
Andrew Hill
Clinical Infectious Diseases (2024)
Closed Access | Times Cited: 3
Weight Gain in HIV Adults Receiving Antiretroviral Treatment: Current Knowledge and Future Perspectives
Konstantinos Markakis, Οlga Tsachouridou, Eleni Georgianou, et al.
Life (2024) Vol. 14, Iss. 11, pp. 1367-1367
Open Access | Times Cited: 3
Eight‐year efficacy and safety of tenofovir alafenamide for treatment of chronic hepatitis B virus infection: Final results from two randomised phase 3 trials
Marı́a Buti, Young‐Suk Lim, Henry Lik‐Yuen Chan, et al.
Alimentary Pharmacology & Therapeutics (2024)
Open Access | Times Cited: 2
Considerations on the associations between antiretroviral regimen and changes in blood pressure in the D2EFT study
Estebán Martínez
Clinical Infectious Diseases (2024)
Closed Access | Times Cited: 1
Effect of Two Forms of Tenofovir on Duodenal Enterocytes – a Hypothesis for Different Effect of TDF and TAF on Body Weight and Plasma Lipids
Kai Juhani Kauppinen, Inka Aho, Nelli Sjöblom, et al.
Clinical Infectious Diseases (2024)
Closed Access | Times Cited: 1
Refining our understanding of the association between integrase inhibitor therapy and elevations in blood pressure
Phyo Pyae Nyein, Kathy Petoumenos, Nila J. Dharan, et al.
Clinical Infectious Diseases (2024)
Closed Access
Where does doravirine fit in current antiretroviral therapy?
Phumla Sinxadi, Gary Maartens
The Lancet HIV (2024) Vol. 11, Iss. 9, pp. e568-e569
Closed Access
“Editorial comment on: Increased incidence of diabetes in people living with HIV treated with first‐line integrase strand transfer inhibitors: A French multicentre retrospective study”
Félix Gutiérrez
HIV Medicine (2024)
Closed Access
“Weight and See”: Initial Weight Gain After Starting Antiretroviral Therapy Is Not Associated With Antiretroviral Regimen Type And Does Not Predict Subsequent Weight Trajectory
Alice Tseng, Leif E. Lovblom, Sharon Walmsley
Open Forum Infectious Diseases (2024) Vol. 12, Iss. 1
Open Access
Page 1

Scroll to top